{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:37:39Z","timestamp":1791005859272,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T00:00:00Z","timestamp":1421020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      The long\u2010term efficacy and safety of canagliflozin, a sodium glucose co\u2010transporter 2 inhibitor, was evaluated over 104\u2009weeks in patients aged 55\u201380\u2009years with type 2 diabetes mellitus (\n                      <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                      ) inadequately controlled on a stable antihyperglycaemic agent regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized, double\u2010blind, phase\n                      <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                      study, patients received canagliflozin 100 or 300\u2009mg or placebo once daily during a 26\u2010week core period (N\u2009=\u2009714) and a 78\u2010week extension period (n\u2009=\u2009624). Efficacy endpoints at week 104 included change from baseline in glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ), fasting plasma glucose (\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      ) and systolic blood pressure, and percent change from baseline in body weight and fasting plasma lipids. Safety was assessed by adverse event (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      ) reports.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 104, canagliflozin 100 and 300\u2009mg were associated with reductions in\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      versus placebo (\u22120.32 and \u22120.43% vs 0.17%, respectively; overall mean baseline, 7.7%) and more patients achieved\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      &lt;7.0% with canagliflozin 100 and 300\u2009mg than with placebo (35.8 and 41.9% vs 20.3%, respectively). Reductions in\n                      <jats:styled-content style=\"fixed-case\">FPG<\/jats:styled-content>\n                      , body weight and systolic blood pressure, and increases in high\u2010density lipoprotein cholesterol (HDL\u2010C) and low\u2010density lipoprotein cholesterol (LDL\u2010C) were seen with canagliflozin compared with placebo. The overall incidence rates of\n                      <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>\n                      over 104\u2009weeks were 88.0, 89.8 and 86.1% with canagliflozin 100 and 300\u2009mg and placebo, respectively; serious\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      rates were low across treatment groups. The incidence rates of urinary tract infections, genital mycotic infections and osmotic diuresis\u2013 and volume depletion\u2013related\n                      <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content>\n                      were higher with canagliflozin than with placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55\u201380\u2009years with\n                      <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                      over 104\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12428","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T08:44:20Z","timestamp":1418460260000},"page":"294-303","source":"Crossref","is-referenced-by-count":191,"title":["Long\u2010term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes"],"prefix":"10.1111","volume":"17","author":[{"given":"B.","family":"Bode","sequence":"first","affiliation":[{"name":"Atlanta Diabetes Associates  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Stenl\u00f6f","sequence":"additional","affiliation":[{"name":"Clinical Trial Centre, Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Western Ontario  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fung","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Usiskin","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Meininger","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68967-8"},{"key":"e_1_2_7_3_1","unstructured":"Centers for Disease Control and Prevention.National diabetes fact sheet.2011. Available from URL:http:\/\/www.cdc.gov\/diabetes\/pubs\/factsheet11.htm. Accessed 7 February 2012."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.26.2.77"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-122"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2012.04.012"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2013.04.1020"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-37"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01558.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01406.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4205"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2753"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.10.1737"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2009.08.002"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_7_27_1","first-page":"LB19","article-title":"Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials (Abstract 69\u2010LB)","volume":"62","author":"Hach T","year":"2013","journal-title":"Diabetes"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"e_1_2_7_29_1","unstructured":"Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals Inc.Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring MD. 10 January 2013."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12187"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02353.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.890925"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12385"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12149"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12428","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:28:21Z","timestamp":1761866901000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/dom.12428"],"URL":"https:\/\/doi.org\/10.1111\/dom.12428","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,12]]}}}